OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has made significant advancements in the clinical development of urcosimod, particularly in its efficacy for pain management. Notably, 67% of patients receiving the 0.05% urcosimod exhibited over a 50% improvement in pain levels, compared to only 33% in the placebo group, with marked reductions in pain scores observed as early as week four. These promising clinical trial outcomes suggest a strong potential for urcosimod to address unmet medical needs in inflammatory eye diseases and chronic pain, contributing positively to the company's growth prospects.

OKYO Pharma Ltd reported a net loss of $4.7 million for the fiscal year ending March 31, 2025, translating to a loss of $0.12 per share, indicating ongoing financial challenges for the company. Additionally, the clinical trial data for urcosimod revealed that all patients in the treatment group experienced moderate to severe pain at baseline, compared to a more favorable baseline for the placebo group, raising concerns about the treatment's efficacy. The company faces significant risks, including the potential failure of urcosimod in clinical trials and regulatory approval, which could hinder its commercial success and lead to dilution of shareholder value.